Keryx Biopharma (KERX) Misses Q3 EPS by 11c

Keryx Biopharma (NASDAQ: KERX) reported Q3 EPS of ($0.38), $0.11 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $256 thousand versus the consensus estimate of $150 thousand.

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity to acquire Harte Hanks for $5.00 per share
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat